The Radiosynthesis Laboratory, Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, USA.
J Labelled Comp Radiopharm. 2024 May 15;67(5):180-185. doi: 10.1002/jlcr.4091. Epub 2024 Apr 11.
Velagliflozin is the active ingredient of the first oral liquid medication approved by the Food and Drug Administration for the treatment of diabetes in cats. This compound belongs to the known class of sodium-glucose cotransporter 2 inhibitors approved to treat diabetes in human. Here, we report the detailed synthesis of velagliflozin labeled with carbon 14 and carbon 13.
维格列汀是首个经美国食品药品监督管理局批准用于治疗猫糖尿病的口服液体制剂的活性成分。该化合物属于已批准用于治疗人类糖尿病的钠-葡萄糖共转运蛋白 2 抑制剂类。在此，我们报道了 14C 和 13C 标记的维格列汀的详细合成过程。
